GOOGLE has made limited changes to its advertising policies to allow CBD topicals to be promoted on its platforms in three jurisdictions – California, Colorado, and Puerto Rico.
A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.
FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks.
A THREE-YEAR neuropathic pain (pre-clinical) study by Cannasouth has confirmed that cannabinoids from medicinal cannabis could be effective at reducing debilitating neuropathic pain, which affects about 400,000 New Zealanders or 8 per cent of the country’s population.
CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for its newly-acquired 7,500sq ft production facility in Sussex, UK.
A FIRST for the UK this week with the announcement that a major study into the potential benefits of cannabis for pain relief is to be launched.
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to present an update on the development of its two lead compounds.
FOLLOWING a two-and-half-year break oil products have returned to the Danish medical cannabis access programme in a move which is likely to provide a boost to the faltering scheme.
UKRAINE is poised permit the use of medical cannabis opening up the potential treatment to over two million people.
